← Back to All current risers

Rgenta Therapeutics, Inc.

On its website, the company describes its work as “Rgenta analyzes vast genomic data with proprietary methods to pinpoint interactions of the splicing machinery and RNA best suited for small molecule binding, designing and…”. Its SEC Form D filed on 2026-11-03 reports US$41,852,307 in securities sold, with a first sale date of 2026-10-19. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.

Appearances
1
Categories
1
First seen
9 November 2026
Latest
9 November 2026
Saved risers · this browser →← All current risersGet this page's badge ↗Open source ↗

Recorded measurements

Published observations only. Missing dates are not zero, and points do not establish what happened between observations. Each source and unit is shown separately.

1 funding or company-rank appearance is not included: those records do not provide comparable dated measurement pairs.

No comparable dated measurements are available for this history.

01/

Appearance history

1 appearance
This page records every appearance of the same entity in the reviewed RiseFinder exports. Rankings keep the original category, period and measurement direction.

Related risers

Latest Funding Rounds From SEC Form D Filings →

If you investigated this riser, tell us what helped—or what was missing.

Share feedback →
02/

Get email updates

Join the list

Get early signals on the websites, apps, repositories and startups gaining momentum. Join the list for RiseFinder email briefings.

By subscribing, you ask us to store your email and send Risefinder updates. You can unsubscribe at any time. Privacy.

Want a sample first? Read past daily emails.